The role of late gadolinium enhancement in predicting arrhythmic events in cardiac sarcoidosis patients – a mini-review

References

• Llanos O, Hamzeh N. Sarcoidosis. Med Clin North Am. 2019;103(3):527–534.
   Web of Science ®Google Scholar
• Birnie DH, Nery PB, Ha AC, et al. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–421.
   PubMed Web of Science ®Google Scholar
• Birnie DH, Kandolin R, Nery PB, et al. Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J. 2017;38(35):2663–2670.
   Web of Science ®Google Scholar
• Ekstrom K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40(37):3121–3128.
   Web of Science ®Google Scholar
• Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.
   PubMed Web of Science ®Google Scholar
• Terasaki F, Azuma A, Anzai T, et al. JCS 2016 guideline on diagnosis and treatment of cardiac Sarcoidosis　- Digest Version. Circ J. 2019;83(11):2329–2388.
   Web of Science ®Google Scholar
• Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–1323.
   PubMed Web of Science ®Google Scholar
• Ribeiro Neto ML, Jellis C, Hachamovitch R, et al. Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: is it time to regroup? Am Heart J. 2020;223:106–109.
   Web of Science ®Google Scholar
• Chiba T, Nakano M, Hasebe Y, et al. Prognosis and risk stratification in cardiac sarcoidosis patients with preserved left ventricular ejection fraction. J Cardiol. 2020;75(1):34–41.
   Web of Science ®Google Scholar
• Okada DR, Smith J, Derakhshan A, et al. Electrophysiology study for risk stratification in patients with cardiac sarcoidosis and abnormal cardiac imaging. Int J Cardiol Heart Vasc. 2019;23:100342.
   Web of Science ®Google Scholar
• Flores RJ, Flaherty KR, Jin Z, et al. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol. 2020;27(6):2003–2010.
   Web of Science ®Google Scholar
• Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4(1):43–48.
   PubMed Web of Science ®Google Scholar
• Halliday BP, Gulati A, Ali A, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22):2106–2115.
   Web of Science ®Google Scholar
• Vassiliou VS, Perperoglou A, Raphael CE, et al. Midwall fibrosis and 5-Year outcome in moderate and severe aortic stenosis. J Am Coll Cardiol. 2017;69(13):1755–1756.
   PubMed Web of Science ®Google Scholar
• Halliday BP, Baksi AJ, Gulati A, et al. Outcome in dilated cardiomyopathy related to the extent, location, and Pattern of Late Gadolinium Enhancement. JACC Cardiovasc Imaging. 2019;12(8 Pt 2):1645–1655.
   Web of Science ®Google Scholar
• Hulten E, Aslam S, Osborne M, et al. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6(1):50–63.
   Web of Science ®Google Scholar
• Komada T, Suzuki K, Ishiguchi H, et al. Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement. Nagoya J Med Sci. 2016;78(4):437–446.
   Web of Science ®Google Scholar
• Smedema JP, Ainslie G, Crijns HJGM. Review: contrast-enhanced magnetic resonance in the diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2020;63(3):271–307.
   Web of Science ®Google Scholar
• Jackson E, Raman S, Crouser ED. Resolution of cardiac magnetic resonance T2 signal following immune suppression for cardiac sarcoidosis: a case series. In: C40 SARCOIDOSIS: UNDERSTANDING THIS MULTI-SYSTEM DISORDER. p. A5025–A5025.
   Google Scholar
• Muser D, Santangeli P, Liang JJ, et al. Characterization of the electroanatomic substrate in cardiac sarcoidosis: correlation with imaging findings of scar and inflammation. JACC Clin Electrophysiol. 2018;4(3):291–303.
   Google Scholar
• Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4(10):1292–1299.
   PubMed Web of Science ®Google Scholar
• Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329–336.
   PubMed Web of Science ®Google Scholar
• Cain MA, Metzl MD, Patel AR, et al. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014;113(9):1556–1560.
   PubMed Web of Science ®Google Scholar
• Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–511.
   PubMed Web of Science ®Google Scholar
• Nadel J, Lancefield T, Voskoboinik A, et al. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging. 2015;16:634–641.
   PubMed Web of Science ®Google Scholar
• Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: Risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738.
   PubMed Web of Science ®Google Scholar
• Ekstrom K, Lehtonen J, Hanninen H, et al. Magnetic resonance imaging as a predictor of survival free of Life-Threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc. 2016;5:e003040.
   Web of Science ®Google Scholar
• Okada DR, Xie E, Assis F, et al. Regional abnormalities on cardiac magnetic resonance imaging and arrhythmic events in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2019;30:1967–1976.
   Web of Science ®Google Scholar
• Yasuda M, Iwanaga Y, Kato T, et al. Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis. Open Heart. 2016;3(2):e000437.
   Google Scholar
• Velangi PS, Chen KA, Kazmirczak F, et al. Right ventricular abnormalities on cardiovascular magnetic resonance imaging in patients with sarcoidosis. JACC Cardiovasc Imaging. 2020;13(6):1395–1405.
   Web of Science ®Google Scholar
• Kagioka Y, Yasuda M, Okune M, et al. Right ventricular involvement is an important prognostic factor and risk stratification tool in suspected cardiac sarcoidosis: analysis by cardiac magnetic resonance imaging. Clin Res Cardiol. 2020;109:988–998.
   Web of Science ®Google Scholar
• Bravo PE, Raghu G, Rosenthal DG, et al. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol. 2017;241:457–462.
   Web of Science ®Google Scholar
• Kouranos V, Tzelepis GE, Rapti A, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10(12):1437–1447.
   PubMed Web of Science ®Google Scholar
• Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and Meta-Analysis. Circ Cardiovasc Imaging. 2016;9:e005001.
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2018;138:e272–e391.
   PubMed Web of Science ®Google Scholar
• Kazmirczak F, Chen KA, Adabag S, et al. Assessment of the 2017 AHA/ACC/HRS guideline recommendations for implantable Cardioverter-Defibrillator implantation in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2019;12(9):e007488.
   PubMed Web of Science ®Google Scholar
• Halawa A, Jain R, Turagam MK, et al. Outcome of implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and Meta-analysis. J Interv Card Electrophysiol. 2020;58(2):233–242.
   PubMed Web of Science ®Google Scholar
• Azoulay LD, Waintraub X, Haroche J, et al. Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: a Meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37:17–23.
   Web of Science ®Google Scholar